Quantum Genomics, (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, in scientific collaboration with Dr. Catherine Llorens-Cortes (INSERM U1050/Collège de France), presented during the Congress HYPERTENSION 2014, held in Athens from June 13th to 16th, the final results of the clinical trials Phase I of its drug candidate QGC001
QGC001 is the first compound of a new class of antihypertensive drugs called BAPAI like «Brain Aminopeptidase A inhibitors». QGC001 aims to propose an alternative treatment of hypertension, especially for patients with a particular hormonal profile characterized by low renin and high vasopressin (LRVH profile), whose blood pressure is more difficult to control with classical blockers of the systemic Renin Angiotensin cascade.
The achieved positive results, especially in terms of tolerance and safety profile, allow to start a Phase II clinical trial in hypertensive patients.
Next meetings of Quantum Genomics
- From June 23rd to 26th 2014, the company will attend BIO (Biotechnology Industry Organization) International Convention in San Diego (USA). This Convention is the world's biggest event for the Biotechnology industry, with more than 1,100 companies attending, including pharmaceutical/biotech corporations and many public research organizations from the USA and 30 other countries.
- On June 25th and 26th 2014, Quantum Genomics will be presenting at the French Life Sciences Days, organized in New York by France Biotech. This conference aims to strengthen the links between listed French Life Sciences companies and North American investors.
Powered by Actusnews Wire (press release services) ©